Federica Peci, Rosjana Pica and Samorindo Peci Abstract Objective: The aim of this study is to investigate whether a 4-week phys¬iotherapeutic rehabilitation combined with transcranial photobiomodulation (tPBM) treatment is more effective than the…
Read MoreSreeja Namilakonda, Sindhu Priya Botta,and Jannu Nikshiptha
Dabigatran is a non-vitamin K antagonist oral anticoagulant (NOAC) whose widespread use for various indications has increased. Intracranial bleed in patients receiving dabigatran is a rare occurrence but can be fatal if reversible agent Idarucizumab is not administered immediately to reverse its effects.
Tessa M Grigg, Ian Culpan, and Wendy Fox-Turnbull
Children’s primitive reflexes typically integrate within the first twelve months of life. If this process is interrupted through maternal or environmental stress, developmental immaturities can occur, leading to educational challenges for children.
Triantafillia Reziti
Although numerous multiple sclerosis (MS) patients display decreased motor performance and cognitive deficits, little is known about rehabilitative methods and assessment strategies.
Jin Jun Luo, William Wallace, and John W. Kusiak
The FDA approved a new drug: lecanemab (or BAN2401, brand name Leqembi, Biogen and Eisai) for treating Alzheimer’s disease (AD) on January 6th, 2023, under the accelerated approval pathway.
Anita K Mehta and Jin Jun Luo
The FDA recently approved a new drug RelyvrioTM (a coformulation of sodium phenylbutyrate and taurursodiol.